Hemoglobin:
Female 12-16g/dL
Male 14-18 g/dL
Hematocrit:
Female 37% - 47%
Male 42% - 52%
Erythropoietin –
kidney produces at same rate of RBC destruction
White blood cells (leukocytes)
5,000-10,000
-Formed in bone marrow
-Provide protection through inflammation & immunity
Neutrophil & Macrophage: Destroy and eliminate foreign invaders
Monocyte: Destruction of bacteria & matures into macrophage
Eosinophil & Basophil: Release chemicals that act on blood vessels to cause tissue level response
Platelets:
50,000-400,000
Form plugs to stop flow of blood at injured site
Spleen
White pulp
Liver
Prothrombin
3 sequential process of controlled blood clotting
Intrinsic factors
Extrinsic factors
Fibrinogen inactive protein made in liver
Active enzyme thrombin removes portions of fibrinogen converting into fibrin
Form into fibrin threads (meshlike base) making blood clot
Hematologic- Aging:
Decreased blood volume
Lower levels of plasma proteins
Bone marrow produces fewer blood cells
Hematologic- Aging: Abnormal findings
Nails beds (capillary refill)
Hair distribution
Skin moisture
Skin color
Patient history
Age, gender, known liver function, hematologic and immunologic disorders
Ask about jaundice, anemia, gallstones may indicate liver problems
Previous radiation therapy may impair hematologic function
Hobbies, occupation exposure to agents affecting bone marrow etc.
Assessment methods:
Patient history Nutritional status Family history Generic risk Current health problems
Nutritional status:
Fats, carbohydrates, protein, iron & vitamins
Vitamin K
Alcohol
Finances
Family history:
Blood/ blood clotting issues inherited
Hemophilia, Sickle Cell Disease
Genetic risk
Sickle Cell trait
Current health problems:
- Shortness of breath on exertion, palpitations, frequent infections, fever
Medications
Blood “thinners” & NSAIDS Anticoagulants Vitamin K antagonists Fibrinolytics Platelet inhibitors
Blood “thinners” & NSAIDS –
change clotting activity, not viscosity
Anticoagulants:
Direct – thrombin inhibitors
Reduces amount of fibrinogen converted into active fibrin
Parenteral & oral
Rivaroxaban (Xarelto), apixaban (Eliquis)
Indirect – thrombin inhibitors
by activating antithrombin III, thrombin is indirectly inhibited
Parenteral
Enoxaparin (Lovenox)
Vitamin K antagonists –
decreases synthesis of Vit K in intestinal tract
Oral
Warfarin (Coumadin)